Sigyn Therapeutics Operating Expenses Growth & History (SIGY)
Sigyn Therapeutics's operating expenses was $2.5M for fiscal 2024.
View full Sigyn Therapeutics company overviewSigyn Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $2.5M | $63,925 | +2.60% |
| 2023 | 2023-12-31 | $2.5M | $308,052 | +14.35% |
| 2022 | 2022-12-31 | $2.1M | $139,048 | +6.92% |
| 2021 | 2021-12-31 | $2.0M | $1.1M | +119.13% |
| 2020 | 2020-12-31 | $916,434 | $290,819 | +46.49% |
| 2019 | 2019-12-31 | $625,615 | −$397,724 | −38.87% |
| 2018 | 2018-12-31 | $1.0M | −$1.0M | −49.97% |
| 2017 | 2017-12-31 | $2.0M | — | — |
| 2015 | 2015-12-31 | $2.3M | $1.9M | +460.47% |
| 2014 | 2014-12-31 | $405,448 | — | — |
Sigyn Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $386,529 | −$421,929 | −52.19% |
| Q2 2025 | 2025-06-30 | $469,513 | −$133,292 | −22.11% |
| Q1 2025 | 2025-03-31 | $546,059 | −$83,913 | −13.32% |
| Q4 2024 | 2024-12-31 | $478,007 | −$239,229 | −33.35% |
| Q3 2024 | 2024-09-30 | $808,458 | $165,644 | +25.77% |
| Q2 2024 | 2024-06-30 | $602,805 | $28,796 | +5.02% |
| Q1 2024 | 2024-03-31 | $629,972 | $108,714 | +20.86% |
| Q4 2023 | 2023-12-31 | $717,236 | $245,649 | +52.09% |
| Q2 2023 | 2023-09-30 | $642,814 | $109,167 | +20.46% |
| Q1 2023 | 2023-06-30 | $574,009 | $41,214 | +7.74% |
| Q4 2022 | 2023-03-31 | $521,258 | −$87,978 | −14.44% |
| Q4 2022 | 2022-12-31 | $471,587 | −$119,353 | −20.20% |
| Q3 2022 | 2022-09-30 | $533,647 | −$39,716 | −6.93% |
| Q2 2022 | 2022-06-30 | $532,795 | $90,977 | +20.59% |
| Q1 2022 | 2022-03-31 | $609,236 | $207,140 | +51.52% |
| Q4 2021 | 2021-12-31 | $590,940 | $246,373 | +71.50% |
| Q3 2021 | 2021-09-30 | $573,363 | $370,386 | +182.48% |
| Q2 2021 | 2021-06-30 | $441,818 | $265,907 | +151.16% |
| Q1 2021 | 2021-03-31 | $402,096 | $209,117 | +108.36% |
| Q4 2020 | 2020-12-31 | $344,567 | $343,017 | +22130.13% |
| Q3 2020 | 2020-09-30 | $202,977 | $56,162 | +38.25% |
| Q2 2020 | 2020-06-30 | $175,911 | $27,095 | +18.21% |
| Q1 2020 | 2020-03-31 | $192,979 | −$8,180 | −4.07% |
| Q4 2019 | 2019-12-31 | $1,550 | −$239,926 | −99.36% |
| Q3 2019 | 2019-09-30 | $146,815 | −$94,489 | −39.16% |
| Q2 2019 | 2019-06-30 | $148,816 | −$90,039 | −37.70% |
| Q1 2019 | 2019-03-31 | $201,159 | −$100,545 | −33.33% |
| Q4 2018 | 2018-12-31 | $241,476 | — | — |
| Q3 2018 | 2018-09-30 | $241,304 | −$496,419 | −67.29% |
| Q2 2018 | 2018-06-30 | $238,855 | −$623,736 | −72.31% |
| Q1 2018 | 2018-03-31 | $301,704 | −$235,393 | −43.83% |
| Q3 2017 | 2017-09-30 | $737,723 | $408,282 | +123.93% |
| Q2 2017 | 2017-06-30 | $862,591 | $335,708 | +63.72% |
| Q1 2017 | 2017-03-31 | $537,097 | −$175,582 | −24.64% |
| Q3 2016 | 2016-09-30 | $329,441 | −$487,117 | −59.65% |
| Q2 2016 | 2016-06-30 | $526,883 | $32,108 | +6.49% |
| Q1 2016 | 2016-03-31 | $712,679 | $553,113 | +346.64% |
| Q4 2015 | 2015-12-31 | $801,507 | — | — |
| Q3 2015 | 2015-09-30 | $816,558 | $729,455 | +837.46% |
| Q2 2015 | 2015-06-30 | $494,775 | — | — |
| Q1 2015 | 2015-03-31 | $159,566 | — | — |
| Q3 2014 | 2014-09-30 | $87,103 | — | — |
Sigyn Therapeutics operating expenses trends
Over the last five fiscal years, Sigyn Therapeutics's operating expenses increased from $625,615 to $2.5M, a change of $1.9M. The latest reported quarter, Q3 2025, shows $386,529.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics source filings ↗